
浏览全部资源
扫码关注微信
1.湖北省十堰市太和医院/湖北医药学院附属医院普外科,湖北 十堰 442000
2.湖北省十堰市郧阳区人民医院胃肠外科,湖北 十堰 442500
3.湖北省十堰市人民医院/湖北医药学院附属人民医院医养中心,湖北 十堰 442000
李恒,E-mail:taiheliheng@163.com
纸质出版日期:2025-02-25,
收稿日期:2024-02-21,
移动端阅览
胡欲飞, 孙越, 付焱, 等. 局部进展期直肠癌新辅助治疗的研究进展[J]. 局解手术学杂志, 2025,34(2):178-182.
HU YU-FEI, SUN YUE, FU YAN, et al. Research progress in neoadjuvant therapy for locally advanced rectal cancer. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 178-182.
胡欲飞, 孙越, 付焱, 等. 局部进展期直肠癌新辅助治疗的研究进展[J]. 局解手术学杂志, 2025,34(2):178-182. DOI: 10.11659/jjssx.02E024043.
HU YU-FEI, SUN YUE, FU YAN, et al. Research progress in neoadjuvant therapy for locally advanced rectal cancer. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 178-182. DOI: 10.11659/jjssx.02E024043.
直肠癌是最常见的消化道恶性肿瘤之一,早期直肠癌患者仅行手术治疗即可达到肿瘤根治的目的,但大多数直肠癌患者就诊时已处于局部进展期阶段。针对这一类人群,单纯通过手术治疗难以获得较好的预后,手术前行干预性放化疗具有重要的临床意义。大量临床研究证明,术前行新辅助治疗可以有效降低肿瘤分期,提高病理完全缓解(pCR)率,极大改善患者的预后。目前,局部进展期直肠癌新辅助治疗的核心手段是放疗、化疗以及新兴的靶向、免疫治疗等,但各种治疗的最佳组合顺序仍存在较大争议,本文就近些年各种新辅助治疗方案进行总结,为直肠癌多学科合作综合治疗提供证据。
Rectal cancer is one of the most common gastrointestinal malignant tumors,and patients with early rectal cancer can achieve radical tumor resection by surgical treatment alone,while most patients with rectal cancer are in the locally advanced stage when admitted to hospital. For this group of people,it is difficult to obtain a good prognosis through surgical treatment alone,and interventional chemoradiotherapy before surgery is of important clinical significance. A large number of clinical studies have proved that preoperative neoadjuvant therapy can effectively reduce tumor stage,increase pathological complete response (pCR) rate,thereby greatly improving the prognosis of patients. At present,the core methods of neoadjuvant therapy for locally advanced rectal cancer are radiotherapy and chemotherapy,as well as the emerging targeted therapy and immunotherapy,while the optimal combination order of various treatments remains in dispute.This article summarizes various neoadjuvant therapy regimens in recent years,in order to provide evidence for the multidisciplinary and comprehensive treatment of rectal cancer.
直肠癌局部进展期新辅助治疗新辅助放化疗
rectal cancerlocally advanced stageneoadjuvant therapyneoadjuvant chemoradiotherapy
Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.doi:10.3322/caac.21660http://dx.doi.org/10.3322/caac.21660.
杨宗明,朱章航,徐李莎,等. 全球结直肠癌疾病负担与筛查比较[J]. 实用肿瘤杂志,2023,38(3):211-217.doi:10.13267/j.cnki.syzlzz.2023.033http://dx.doi.org/10.13267/j.cnki.syzlzz.2023.033.
Siegel RL,Miller KD,Fuchs HE,et al. Cancer statistics,2022[J]. CA Cancer J Clin,2022,72(1):7-33.doi:10.3322/caac.21708http://dx.doi.org/10.3322/caac.21708.
中国临床肿瘤学会(CSCO)结直肠癌专家委员会.可切除的进展期结直肠癌围手术期治疗专家共识(2019)[J]. 中华胃肠外科杂志,2019,22(8):701-710.doi:10.3760/cma.j.issn.1671-0274.2019.08.001http://dx.doi.org/10.3760/cma.j.issn.1671-0274.2019.08.001.
Oronsky B,Reid T,Larson C,et al. Locally advanced rectal cancer: the past,present,and future[J]. Semin Oncol,2020,47(1):85-92.doi:10.1053/j.seminoncol.2020.02.001http://dx.doi.org/10.1053/j.seminoncol.2020.02.001.
Sineshaw HM,Jemal A,Thomas CJ,et al. Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: an analysis from the National Cancer Data Base[J]. Cancer,2016,122(13):1996-2003.doi:10.1002/cncr.29993http://dx.doi.org/10.1002/cncr.29993.
Benson AB,Venook AP,Al-Hawary MM,et al. NCCN guidelines insights: rectal cancer,version 6.2020[J]. J Natl Compr Canc Netw,2020,18(7):806-815.doi:10.6004/jnccn.2020.0032http://dx.doi.org/10.6004/jnccn.2020.0032.
国家卫生健康委员会医政司,中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2023版)[J]. 协和医学杂志,2023,14(4):706-733.doi:10.12290/xhyxzz.2023-0315http://dx.doi.org/10.12290/xhyxzz.2023-0315.
Koukourakis IM,Kouloulias V,Tiniakos D,et al. Current status of locally advanced rectal cancer therapy and future prospects[J].Crit Rev Oncol Hematol,2023,186:103992.doi:10.1016/j.critrevonc. 2023.103992http://dx.doi.org/10.1016/j.critrevonc.2023.103992.
Sun XY,Cai SH,Xu L,et al. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage Ⅲb/Ⅲc locally advanced rectal cancer: a retrospective single-institution study with propensity score-matched comparative analysis[J]. Asia Pac J Clin Oncol,2020,16(3):142-149.doi:10.1111/ajco.13306http://dx.doi.org/10.1111/ajco.13306.
Zhang Y,Sun Y,Xu Z,et al. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: a comparative analysis after propensity score matching[J]. Eur J Surg Oncol,2017,43(8):1440-1446.doi:10.1016/j.ejso.2017.04.007http://dx.doi.org/10.1016/j.ejso.2017.04.007.
Glynne-Jones R,Wyrwicz L,Tiret E,et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2018,29(Suppl 4):iv263.doi:10.1093/annonc/mdy161http://dx.doi.org/10.1093/annonc/mdy161.
Cambray M,Gonzalez-Viguera J,Berenguer MA,et al. Short-course radiotherapy in locally advanced rectal cancer[J]. Clin Transl Gastroenterol,2020,11(6):e162.doi:10.14309/ctg.000000000 0000162http://dx.doi.org/10.14309/ctg.0000000000000162.
曾庆范,张帆,王颖拓. 局部进展期直肠癌患者术前短程放疗与同步放化疗的效果对比[J]. 中国肛肠病杂志,2022,42(5):4-6.doi:10.3969/j.issn.1000-1174.2022.05.002http://dx.doi.org/10.3969/j.issn.1000-1174.2022.05.002.
黄斌杰,秦启元,马腾辉. 放疗相关直肠吻合口并发症的外科预防及治疗[J]. 中国实用外科杂志,2023,43(10):1122-1125.doi:10.19538/j.cjps.issn1005-2208.2023.10.09http://dx.doi.org/10.19538/j.cjps.issn1005-2208.2023.10.09.
Mowery YM,Salama JK,Zafar SY,et al. Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States[J].Cancer,2017,123(8):1434-1441.doi:10.1002/cncr.30461http://dx.doi.org/10.1002/cncr.30461.
Raldow AC,Chen AB,Russell M,et al.Cost-effectiveness of short-course radiation therapy vs long-course chemoradiation for locally advanced rectal cancer[J]. JAMA Netw Open,2019,2(4):e192249.doi:10.1001/jamanetworkopen.2019.2249http://dx.doi.org/10.1001/jamanetworkopen.2019.2249.
杨彦,谭昌静,杨效东,等. 术前改良短程放疗联合卡培他滨对腹腔镜直肠癌低位前切除术患者近远期疗效和安全性的影响分析[J]. 中国医学前沿杂志(电子版),2021,13(10):126-130.doi:10.12037/YXQY.2021.10-26http://dx.doi.org/10.12037/YXQY.2021.10-26.
Bujko K,Wyrwicz L,Rutkowski A,et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase Ⅲstudy[J]. Ann Oncol,2016,27(5):834-842.doi:10.1093/annonc/mdw062http://dx.doi.org/10.1093/annonc/mdw062.
陈诚,冉文华,张敬,等. 术前短程放疗与术前同步放化疗用于局部进展期直肠癌临床疗效比较[J]. 中国药业,2020,29(18):73-75.doi:10.3969/j.issn.1006-4931.2020.18.025http://dx.doi.org/10.3969/j.issn.1006-4931.2020.18.025.
Erlandsson J,Holm T,Pettersson D,et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm Ⅲ): a multicentre,randomised,non-blinded,phase 3,non-inferiority trial[J]. Lancet Oncol,2017,18(3):336-346.doi:10.1016/S1470-2045(17)30086-4http://dx.doi.org/10.1016/S1470-2045(17)30086-4.
Erlandsson J,Fuentes S,Radu C,et al. Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm Ⅲ trial[J]. BJS Open,2021,5(6):zrab137.doi:10.1093/bjsopen/zrab137http://dx.doi.org/10.1093/bjsopen/zrab137.
Abdel-Rahman O,Kumar A,Kennecke HF,et al. Impact of duration of neoadjuvant radiation on rectal cancer survival: a real world multi-center retrospective cohort study[J]. Clin Colorectal Cancer,2018,17(1):e21-e28.doi:10.1016/j.clcc.2017.06.003http://dx.doi.org/10.1016/j.clcc.2017.06.003.
Martling A,Smedby KE,Birgisson H,et al. Risk of second primary cancer in patients treated with radiotherapy for rectal cancer[J]. Br J Surg,2017,104(3):278-287.doi:10.1002/bjs.10327http://dx.doi.org/10.1002/bjs.10327.
Svanström RA,Buchli C,Bottai M,et al. Effect of radiotherapy for rectal cancer on female sexual function: a prospective cohort study[J]. Br J Surg,2020,107(5):525-536.doi:10.1002/bjs.11373http://dx.doi.org/10.1002/bjs.11373.
Margalit O,Mamtani R,Lawrence YR,et al. Locally advanced rectal adenocarcinoma: are preoperative short and long course radiotherapy truly equivalent?[J]. Mol Clin Oncol,2019,10(5):555-559.doi:10.3892/mco.2019.1825http://dx.doi.org/10.3892/mco.2019.1825.
Schrag D,Weiser MR,Goodman KA,et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial[J]. J Clin Oncol,2014,32(6):513-518.doi:10.1200/JCO.2013.51.7904http://dx.doi.org/10.1200/JCO.2013.51.7904.
Deng Y,Chi P,Lan P,et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter,open-label,randomized three-arm phase Ⅲ trial[J]. J Clin Oncol,2016,34(27):3300-3307.doi:10.1200/JCO.2016.66.6198http://dx.doi.org/10.1200/JCO.2016.66.6198.
Deng Y,Chi P,Lan P,et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial[J]. J Clin Oncol,2019,37(34):3223-3233.doi:10.1200/JCO.18.02309http://dx.doi.org/10.1200/JCO.18.02309.
王少怡,柏强善,陈安. 单纯新辅助化疗治疗进展期低位直肠癌的疗效分析[J]. 现代肿瘤医学,2023,31(18):3411-3415.doi:10.3969/j.issn.1672-4992.2023.18.014http://dx.doi.org/10.3969/j.issn.1672-4992.2023.18.014.
Miwa K,Oki E,Enomoto M,et al. Randomized phase Ⅱ study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)[J]. BMC Cancer,2021,21(1):23.doi:10.1186/s12885-020-07766-5http://dx.doi.org/10.1186/s12885-020-07766-5.
中国南方肿瘤临床研究协会结直肠癌专业委员会. 结直肠癌改良三药cmFOLFOXIRI方案临床应用中国专家共识[J]. 中华胃肠外科杂志,2021,24(6):473-479.doi:10.3760/cma.j.cn.441530-20210209-00060http://dx.doi.org/10.3760/cma.j.cn.441530-20210209-00060.
Tokuhara K,Matsui Y,Ueyama Y,et al. Feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. J Anus Rectum Colon,2022,6(1):24-31.doi:10.23922/jarc.2021-033http://dx.doi.org/10.23922/jarc.2021-033.
周荻,周珺珺,胡斌,等. 局部进展期直肠癌的全程新辅助治疗模式[J]. 解放军医学杂志,2024,49(1):17-22.doi:10.11855/j.issn.0577-7402.2369.2023.0619http://dx.doi.org/10.11855/j.issn.0577-7402.2369.2023.0619.
任文豪,韩文静,许粤明. 术前短程放疗序贯化疗与长程放疗同步化疗对Ⅱ/Ⅲ期中低位直肠癌的疗效比较[J]. 中国现代普通外科进展,2023,26(6):485-488.doi:10.3969/j.issn.1009-9905.2023.06.017http://dx.doi.org/10.3969/j.issn.1009-9905.2023.06.017.
曲智锋,徐远,原翔. Ⅲb期直肠癌术前短程放疗与术前长程放疗分别联合化疗疗效的随机对照研究[J]. 现代肿瘤医学,2021,29(11):1923-1928.doi:10.3969/j.issn.1672-4992.2021.11.020http://dx.doi.org/10.3969/j.issn.1672-4992.2021.11.020.
Jin J,Tang Y,Hu C,et al. Multicenter,randomized,phase Ⅲ trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)[J].J Clin Oncol,2022,40(15):1681-1692.doi:10.1200/JCO.21.01667http://dx.doi.org/10.1200/JCO.21.01667.
Kim JK,Marco MR,Roxburgh C,et al. Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer[J]. Oncologist,2022,27(5):380-388.doi:10.1093/oncolo/oyac025http://dx.doi.org/10.1093/oncolo/oyac025.
Song J,Wang Y,Yu H,et al. Neoadjuvant chemotherapy plus bevacizumab combined with total mesorectal excision in treating locally advanced rectal cancer patients with BRAF mutation: clinical benefit and safety[J]. Comput Math Methods Med,2021:4227650.doi:10.1155/2021/4227650http://dx.doi.org/10.1155/2021/4227650.
中国医师协会结直肠肿瘤专业委员会,中国抗癌协会大肠癌专业委员会,国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会. 结直肠癌靶向治疗中国专家共识[J].中华普通外科学文献(电子版),2023,17(1):1-8.doi:10.3877/cma.j.issn.1674-0793. 2023.01.001http://dx.doi.org/10.3877/cma.j.issn.1674-0793.2023.01.001.
Kripp M,Horisberger K,Mai S,et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase Ⅱ trials[J]. Gastroenterol Res Pract,2015:273489.doi:10.1155/2015/273489http://dx.doi.org/10.1155/2015/273489.
李鹏飞,韩天赐. 非小细胞肺癌新辅助免疫治疗在临床中的应用进展[J]. 中国现代医学杂志,2024,34(2):1-5.doi:10.3969/j.issn.1005-8982.2024.02.001http://dx.doi.org/10.3969/j.issn.1005-8982.2024.02.001.
Friedlaender A,Naidoo J,Banna GL,et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC[J]. Cancer Treat Rev,2022,104:102350.doi:10.1016/j.ctrv.2022.102350http://dx.doi.org/10.1016/j.ctrv.2022.102350.
Shu Y,Zheng S. The current status and prospect of immunotherapy in colorectal cancer[J]. Clin Transl Oncol,2024,26(1):39-51.doi:10.1007/s12094-023-03235-0http://dx.doi.org/10.1007/s12094-023-03235-0.
Tominaga T,Akiyoshi T,Yamamoto N,et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy[J]. PLoS One,2019,14(2):e212978.doi:10.1371/journal.pone.0212978http://dx.doi.org/10.1371/journal.pone.0212978.
Topalian SL,Taube JM,Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science,2020,367(6477):eaax0182.doi:10.1126/science.aax0182http://dx.doi.org/10.1126/science.aax0182.
Lin Z,Cai M,Zhang P,et al. PhaseⅡ,single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J]. J Immunother Cancer,2022,10(2):e003554corr1. doi: 10.1136/jitc-2021-003554corr1http://dx.doi.org/10.1136/jitc-2021-003554corr1.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621